University of Mississippi

eGrove

Faculty and Student Publications

Psychology

8-12-2022

No association between perinatal mood disorders and hypertensive pregnancies

Sarah Araji University of Mississippi Medical Center

Ashley Griffin University of Mississippi Medical Center

Wondwosen Kassahun-Yimer University of Mississippi Medical Center

Laura Dixon University of Mississippi

Shauna Kay Spencer University of Mississippi Medical Center

See next page for additional authors

Follow this and additional works at: https://egrove.olemiss.edu/psych_facpubs

Part of the Psychology Commons

Recommended Citation

Araji, S., Griffin, A., Kassahun-Yimer, W., Dixon, L., Spencer, S.-K., Belk, S., Ohaegbulam, G., & Wallace, K. (2022). No association between perinatal mood disorders and hypertensive pregnancies. Frontiers in Psychiatry, 13, 898003. https://doi.org/10.3389/fpsyt.2022.898003

This Article is brought to you for free and open access by the Psychology at eGrove. It has been accepted for inclusion in Faculty and Student Publications by an authorized administrator of eGrove. For more information, please contact egrove@olemiss.edu.

Authors

Sarah Araji, Ashley Griffin, Wondwosen Kassahun-Yimer, Laura Dixon, Shauna Kay Spencer, Sheila Belk, Gail Ohaegbulam, and Kedra Wallace

Check for updates

OPEN ACCESS

EDITED BY Karen Tabb, University of Illinois Urbana-Champaign, United States

REVIEWED BY Jochen Einbeck, Durham University, United Kingdom Kay Matthews, Independent Researcher, Houston, TX, United States

*CORRESPONDENCE Kedra Wallace kwallace2@umc.edu

SPECIALTY SECTION

This article was submitted to Mood Disorders, a section of the journal Frontiers in Psychiatry

RECEIVED 16 March 2022 ACCEPTED 25 July 2022 PUBLISHED 12 August 2022

CITATION

Araji S, Griffin A, Kassahun-Yimer W, Dixon L, Spencer S-K, Belk S, Ohaegbulam G and Wallace K (2022) No association between perinatal mood disorders and hypertensive pregnancies. *Front. Psychiatry* 13:898003. doi: 10.3389/fpsyt.2022.898003

COPYRIGHT

© 2022 Araji, Griffin, Kassahun-Yimer, Dixon, Spencer, Belk, Ohaegbulam and Wallace. This is an open-access article distributed under the terms of the Creative Commons Attribution License

(CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

No association between perinatal mood disorders and hypertensive pregnancies

Sarah Araji¹, Ashley Griffin², Wondwosen Kassahun-Yimer³, Laura Dixon⁴, Shauna-Kay Spencer^{1,5}, Sheila Belk⁵, Gail Ohaegbulam¹ and Kedra Wallace^{1,5,6*}

¹Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, MS, United States, ²Program in Neuroscience, School of Graduate Studies in Health Sciences, University of Mississippi Medical Center, Jackson, MS, United States, ³John D. Bower School of Population Health, Department of Data Science, University of Mississippi Medical Center, Jackson, MS, United States, ⁴Department of Psychology, University of Mississippi Medical Center, Jackson, MS, ⁵Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS, United States, ⁶Myrlie Evers-Williams Institute for the Elimination of Health Disparities, University of Mississippi Medical Center, Jackson, MS, United States

Mental health disorders such as anxiety and/or depression are the most common mental health disorders seen among reproductive aged women and can increase during pregnancy. Many sociodemographic risk factors have been associated with anxiety and/or depression in pregnancy, which can lead to adverse maternal and infant outcomes including the risk of a hypertensive pregnancy. The current study prospectively examined selfreported anxiety, depression and stress in pregnant women without a history of fetal loss or mood disorders beginning at 20-26 weeks. At each study visit, circulating immune factors associated with perinatal mood disorders were measured in blood samples that were collected. A total of 65 women were eligible for data analysis, 26 of which had hypertensive pregnancies. There was not a significant difference in self-reported depression, anxiety or stress between hypertensive disorders of pregnancy and normotensive women. Black women were more likely to have a hypertensive pregnancy and develop a perinatal mood disorder compared to non-black women. Both the inflammatory cytokines interleukin-17 and tumor necrosis factoralpha were increased in patients with perinatal mood disorders. However, additional research is needed in a larger sample to truly understand the relationship between these factors along with the underlying etiologies and the associated outcomes.

KEYWORDS

anxiety, depression, interleukin-17, social determinants of health, stress, tumor necrosis factor

Introduction

Maternal mental health is a significant public health challenge, with 10% of pregnant women and 13% of postpartum women experiencing a mental health problem. Pregnancy causes several transformations in women's bodies including an increased hormonal environment that contributes to a myriad of psychological and physical health changes. Maternal mental health has recently gained more research interest given the association with adverse maternal and fetal outcomes. For instance, preterm labor, low birth weight and fetal growth restriction have all been associated with anxiety or depression during pregnancy (1, 2). Perinatal mood and anxiety disorders (PMADs) are the most common mental health disorders seen in women of reproductive age (3). They have an impact on maternal and fetal wellbeing as well as adverse outcomes in children (4).

The pathogenesis of PMADs are complex and encompass a wide group of risk factors including history of mental disorders, social determinants of health and biological risk factors (2). Multiple studies have consistently found that depression in the antenatal period is a strong risk factor for developing postpartum depression (5) and that hypertensive disorders of pregnancy (HDP) can lead to physiological changes that might play a role in triggering anxiety and/or depressive episodes (2). Previous research has also found that women who have anxiety disorders or depression, diagnosed either before or during pregnancy are at an increased risk of developing a HDP (6, 7). However, these studies have always examined populations of women with a low incidence of HDP, so the directionality of HDP or PMAD is hard to determine. Therefore, the objective of the current study was to determine the relationship between PMAD and HDP in a population of women who are at an increased environmental risk for developing a HDP. According to the Center for Diseases Control Mississippi, a primarily rural state located in the Southern portion of the United States, is constantly ranked #1 or #2 in the United States for hypertension related deaths and the number of hypertensive adults (43.6% of adult population is hypertensive). The high rate of hypertension in Mississippi, makes this an ideal environment to evaluate the relationship between HDP and PMADs. Based on prior research, we investigated whether women with evidence of PMADs are at an increased risk of experiencing a HDP or worse labor outcomes. We hypothesize that women who have increased antepartum PMADs will have a HDP and more immune activation compared to women without antepartum anxiety and/or depression.

Materials and methods

Study design

This was a prospective study approved by the Institutional Review Board (IRB) at the University of Mississippi Medical Center in Jackson, MS. Participants were recruited from August 2018 to June 2020 from outpatient clinics affiliated with the University. Written informed consent was obtained from all study participants who met the inclusion/exclusion criteria. Women between 18 and 40 years of age were eligible if they were between 20 and 26 weeks pregnant at recruitment with a single fetus free from fetal anomalies. Participants were excluded if they had a history of stillbirth, fetal death or loss of a child, history of alcohol or drug abuse, HIV/AIDS, history of preterm birth, or history of a high-risk pregnancy (i.e., preeclampsia; PreE). Also to ensure that we were only examining women with new cases of anxiety/depression a history or current diagnosis of anxiety/depression and/or a psychosis was also an exclusion factor. All of these factors have been reported to contribute to the development of PMAD so they were excluded for this initial study. In the current analysis women who met or exceeded the cut-off on either the PASS or EPDS were categorized as PMAD.

Procedure and instruments used to evaluate stress, depression and anxiety

As outlined in the Figure 1, women completed two study visits (recruitment and 10 weeks postrecruitment) and a series of validated questionnaires were administered to assess stress (Perceived Stress Scale; PSS), depression (Edinburgh Postnatal Depression Scale; EPDS) and anxiety (Perinatal Anxiety Screening Scale; PASS) were completed.

- The PSS is a validated 14-item self-reported questionnaire used to assess one's perception of the extent of stress in one's life. Respondents rate the frequency of their feelings and thoughts about life situations over the month using a fivepoint Likert-type scale (0-never, 4-very often). This survey is not used for diagnosis but as a clinical screening tool for stress. Items are summed, and a score between 14 and 26 indicates moderate stress and 27–40 indicates high levels of stress (8).
- The EPDS is a clinical screening tool validated to screen for depression both during pregnancy and in the postpartum period (9). It is a 10-item self-report questionnaire in which women rate their feelings over the past 7 days. Each question is scored 0–3 (score range 0–30) and it is quick to

complete. The cut-off value of \geq 12 was used for probable depression (10).

• The PASS is a validated 38-item self-report questionnaire used to screen for anxiety over the past month among pregnant women. Respondents rate symptoms of acute anxiety and adjustment, general worry and specific fears, perfectionism, trauma and control, and social anxiety on a four-point Likert-type scale (0-not at all, 3-all the time). The cut-off scores for mild to moderate anxiety is 0–21, moderate to severe 21–41 and 42–93 for severe anxiety (11, 12).

Women who exceeded the cut-off scores were provided feedback on their study results and offered additional mental health resources outside of the study.

Participants also completed a survey of sociodemographic characteristics (i.e., employment and relationship status, education level). To evaluate socioeconomic status, we utilized the distressed community index (DCI). The DCI measures economic wellbeing at a zip code level by assessing location based disparities and evaluating the relationship between them and health outcomes, demographics and educational level (13). Communities are scored and divided into five tiers based on these distressed levels: prosperous (\leq 20.0), comfortable (20.1–40.0), mid-tier (40.1–60.0), at risk (60.1–80.0) and distressed (> 80.0).

Data entry and collection

Health data was extracted from electronic medical records, and all data were stored in REDCap (14). The following electronic health data was collected: residential zip code, medical history including details on obstetric characteristics; body mass index (BMI), labor and delivery details, and final hypertensive status (e.g., PreE, gestational hypertension). Intrapartum complications such as fever, postpartum hemorrhage, and shoulder dystocia were also collected. From infant records the following was collected: birth weight and information pertaining to presence of infant complications at birth.

Study groups

After all women had completed the study, participants were grouped based on the hypertensive status at the time of discharge from labor and delivery. Women were categorized as normotensive pregnancy (n = 39) or hypertensive pregnancy (n = 26). Women were considered to have a hypertensive pregnancy if they had chronic hypertension (cHTN), gestational hypertension (gHTN), PreE or super-imposed PreE (siPreE).

Blood collection and quantification of circulating cytokines

At each study visit blood was collected by a study nurse or a member of the facility laboratory. Samples were collected in EDTA (BD, United States) and serum collection tubes and allowed to clot. Tubes were centrifuged at 2,000 RPM at 4°C for 20 min, aliquoted and frozen at -20°C. Maternal plasma levels of specific cytokines were measured using commercially available Human Premixed Multi-Analyte Magnetic Luminex Assay (R&D systems, United States) and assayed in duplicate according to the manufacturers recommendations. Multiplex panels were designed for the following proteins and cytokines, all of which are associated with perinatal anxiety and depression or hypertensive pregnancy (15-17): soluble fmslike tyrosine kinase-1 (sFlt-1), soluble endoglin (sEng) and placental growth factor (PIGF). All Luminex assays were read and analyzed via the Luminex MAGPIX analyzer. Interleukin-17 (IL-17, Boster Bio, CA, United States) and tumor necrosis factor-alpha (TNF-a; RayBiotech, GA, United States) were measured via individual ELISAs according to the manufacturer's protocol.

Data analysis

Summary statistics were presented as means (standard deviations) for continuous variables and using frequencies and percentages for categorical variables. Correlation among continuous variables was estimated using Pearson's correlation coefficient. Chi-square test, Fisher's exact tests, T-test were used to compare participant characteristics between HDP and Normotensive categories. Similar statistical tests were used to compare demographic characteristics of women among PMAD and non-PMAD categories. Multivariable adjusted logistic regression models were used to assess associations between HDP, maternal age, maternal BMI and race. Data for EPDS, PASS and PSS scores were presented at Visit 1 and Visit 2 for all women as well as by HDP and Normotensive categories. All statistical analyses were performed with SAS version 9.4 (SAS Institute Inc., Cary, NC, United States). A two-sided p < 0.05 was considered statistically significant.

Results

A total of 76 women enrolled in the study. Eleven women were removed for either delivering at an outside hospital (n = 3), lost to follow-up (n = 1), or did not meet inclusion/exclusion criteria upon chart review (n = 7); leaving a total of 65 women remaining in the study (**Figure 1**). Eight women were not seen at visit 2 because they had a preterm delivery.



TABLE 1 Sociodemographic characteristics of study participants at baseline (visit 1).

TABLE 2	Birth outcomes between women with normotensive
pregnand	ies and hypertensive disorders of pregnancy (HDP).

	Normotensive $(n = 39)$	HDP (<i>n</i> = 26)	P-value
Age (years)	25.97 ± 4.36	29.57 ± 5.87	0.006
Maternal race (%)			0.0007
Black	46.2	84.5	
White	51.2	11.5	
Other	2.6	3.8	
Gestational age (weeks)	23.07 ± 2.02	23.72 ± 1.7	0.19
BMI (kg/m ²)	31.34 ± 8.09	41.9 ± 13.5	0.0002
Education (%)			0.61
High school	31.6	18.5	
Diploma/GED	26.3	37.0	
Some college	13.2	18.5	
Technical/community	10.5	14.8	
college degree	18.4	11.2	
Bachelor's degree			
Master's degree or			
beyond			
Relationship (%)			0.01
Married	56.4	30.8	
Single	12.8	34.6	
In a relationship	30.8	23.1	
Other	0	11.5	
Employment			0.17
Employed FT/PT/on	71.1	59.3	
leave/student	15.7	33.3	
Not currently working	13.2	7.4	
Homemaker/disabled			
Distressed community			0.76
index (%)	7.7	3.8	
Prosperous	15.4	7.7	
Comfortable	7.7	3.8	
Mid-tier	15.4	19.2	
At-risk	53.8	65.5	
Distressed			

	Normotensive $(n = 39)$	$\begin{array}{l}\text{HDP}\\(n=26)\end{array}$	P-value
Gestational age at delivery	38.04 ± 2.15	35.59 ± 3.17	0.0004
(weeks)			
Preterm birth (%)			0.0001
No	81.6	33.3	
Yes	18.4	66.7	
Mode of delivery (%)			0.12
Vaginal	67.57	46.15	
Cesarean section	34.2	53.85	
Labor complications (%)			0.34
No	69.23	80	
Yes	30.77	20	
Birthweight (g)	3226.7 ± 591.3	2781.3 ± 721	0.009
Infant complications (%)			0.25
No	91.4	76.4	
Yes	8.6	23.8	

Women who were black, older and obese were more likely to experience a hypertensive disorders of pregnancy

The baseline sociodemographic characteristics of study participants participating in the study are shown in **Table 1**. Women who had a HDP were significantly older (p = 0.006) and had a higher BMI (41.9 \pm 13.5 kg/m², p = 0.0002) relative to women with normotensive pregnancies. There was a significant difference in the racial distribution between women experiencing HDP and normotensive pregnancies (p = 0.0007). As shown in **Table 1**, black women comprised 84.5% of HDP while white women comprised 51.2% of normotensive

TABLE 3 Scores for EPDS, PASS, and PSS were divided into different			
categories based on cut-off scores and the number of women were			
compared between normotensive pregnancies and hypertensive			
disorders of pregnancy (HDP).			

	All	Normotensive HDP		<i>P</i> -
	women	(<i>n</i> = 39)	(n = 26)	value
EPDS (%)				
Visit 1	83.1	84.21	81.48	0.99
Low risk (0–11)	16.9	15.79	18.52	0.99
Probable depression	84.2	85.29	82.61	
(12-30)	15.8	14.71	17.39	
Visit 2				
Low risk (0–11)				
Probable depression				
(12-30)				
PASS (%)				
Visit 1	65.6	56.76	77.78	0.11
Minimal (0-20)	34.4	43.24	22.22	0.07
Moderate/Severe	73.7	64.71	86.96	
(21-93)	26.3	35.29	13.04	
Visit 2				
Minimal (0-20)				
Moderate/Severe				
(21-93)				
PSS (%)				
Visit 1	9.2	5.26	14.81	0.22
Minimal (0-13)	90.8	94.74	85.19	0.09
Moderate/Severe	19.3	11.76	30.43	
(14-40)	80.7	88.24	69.57	
Visit 2				
Minimal (0-13)				
Moderate/Severe				
(14-40)				

The point range for each categorization within the instruments is listed in parentheses.

pregnancies. Multiple logistic regression showed that women who were older (p = 0.02), had a higher BMI (p = 0.01) or who were of black race (p = 0.01) had significant odds of having a HDP (**Supplementary Table 1**).

There was not a significant difference in self-report There was a significant difference in relationship status, as women who had a HDP were less likely to be married and more likely to be single compared to women with a normotensive pregnancy (p = 0.01). However, no differences were found between the groups in relation to education level (p = 0.61), current employment status (p = 0.17) or their DCI (p = 0.76).

Women with a hypertensive disorders of pregnancy delivered earlier and had lower birth weight infants

Women with a HDP gave birth significantly earlier $(35.59 \pm 3.17 \text{ weeks})$ than normotensive women $(38.04 \pm 2.15 \text{ weeks}, p = 0.0004;$ Table 2). This corresponded to a higher incidence of preterm birth (p = 0.0001) and a significantly lower infant birth weight among women with

HDP (p = 0.009; Table 2). Despite the higher rate of preterm delivery there were no differences in mode of delivery (p = 0.12), maternal labor complications (p = 0.34) or infant complications (p = 0.25) between the two groups of women.

Women with hypertensive disorders of pregnancy did not have increased depression, anxiety or perceived stress

There was not a significant difference in self-reported depression, anxiety or stress between HDP and normotensive women at either visit 1 or visit 2. Women were also ranked as low depression vs. probable depression based on their EPDS value. Although 16.9% of women were at risk for probable depression, no significant differences were observed between normotensive and HDP pregnancies when this relationship was further examined (p = 0.99, **Table 3**). Results from the PASS was used to evaluate minimal anxiety vs. moderate/severe anxiety among women with normotensive and HDP pregnancies at visits 1 and 2. At both visits women with normotensive pregnancies were more likely to screen with moderate/severe anxiety relative to women with a HDP (p = 0.11 at visit 1; p = 0.07 at visit 2).

Likewise, perceived stress decreased in both group of women between visits 1 (p = 0.22) and 2 (p = 0.09), with normotensive women being more likely to report higher levels of stress relative to women with a HDP (Table 3).

Among HDP women, 53.8% (n = 14) women had PreE vs. a diagnosis of cHTN/gHTN (n = 12). There were no statistically significant differences between women in any of the demographic factors with the exception of BMI. Women who developed PreE/siPreE were significantly heavier at the time of enrollment (48.14 ± 15.1 vs. 36.12 ± 8.5 kg/m²; **Supplementary Table 2**) compared to women with cHTN/gHTN. When labor complications were examined, women with PreE/siPreE were more likely to have a preterm delivery relative to women with cHTN/gHTN (78.6 vs. 25%, p = 0.02; **Supplementary Table 2**). However, there were not any significant differences between any other variables. Women with PreE/siPreE were also not more likely to have a PMAD at either visit 1 (p = 0.99) or visit 2 (p = 0.99).

Perinatal mood and anxiety disorder was not associated with lower socioeconomic factors or worst birth outcomes

In the current analysis there 27 women were categorized as PMAD and compared to 38 non-PMAD women. There was not

a significant relationship between HDP and PMAD at either visit 1 (p = 0.21) or visit 2 (p = 0.07). The overall percent of women with a PMAD decreased 16% (p = 0.06) between visit 1 and visit 2 regardless of their hypertensive status, with no significant changes in outcomes due to a change in PMAD status.

No significant differences were found in baseline demographic factors between women who had a PMAD and those who did not (Table 4). However, when race was collapsed into black vs. non-black, black women were 40% more likely to report a PMAD, O.R. 1.39 95% CI (0.54-3.63) relative to non-black women. Current employment status (p = 0.39) or education level (p = 0.62) did not have an impact on PMAD, with the majority of women experiencing a PMAD (59%) having completed a high school diploma/GED or some college (Table 4). Relationship status also had no significant impact on PMAD (p = 0.11). DCI was not associated with PMAD (p = 0.12) as the majority of women lived in at risk or distressed communities regardless of their PMAD status. Experiencing a PMAD was not associated with an increased gestational age at delivery (p = 0.51), pre-term birth (p = 0.43) or decreased infant birth weight (p = 0.53, Table 4). Similarly women with PMAD did not experience more labor complications (p = 0.15) or infant complications (p = 0.71) relative to women without PMAD (Table 4).

Perceived stress was higher in women with perinatal mood and anxiety disorders

A significant relationship was found between PSS and PMAD, as women with PMADs had significantly higher levels of PSS at both visit 1 (p < 0.0001) and visit 2 (p < 0.0001) relative to women without PMADs. Additionally, the mean level of PSS did not significantly change between visit 1 and visit 2 among women with (p = 0.99) or without PMADs (p = 0.94; Figure 2A). To further explore the impact of perceived stress, we examined the levels of perceived stress and demographic factors.

At both visit 1 (p = 0.006) and visit 2 (p = 0.03) women who were married were more likely to experience moderate levels of stress, while non-married women in relationships or who were single were more likely to experience severe levels of stress (**Figure 2B**). Interestingly, a significant relationship was found between PSS and DCI at visit 2 (p = 0.02), however, upon further examination it was found that 68.9% of the women (22/32) living in distressed zip codes reported moderatesevere stress. However, PSS was not significantly associated with any other socioeconomic or demographic factors nor was it associated with labor or birth outcomes (**Supplementary Data**). TABLE 4 Sociodemographic and labor characteristics between women with and without perinatal mood and anxiety disorders (PMAD).

	Non-PMAD $(n = 38)$	PMAD (<i>n</i> = 27)	P-value
Age (years)	28.34 ± 5.2	26.37 ± 5.38	0.14
Maternal race (%)			0.30
Black	55.3	70.4	
White	39.5	29.6	
Other	5.2	0	
BMI (kg/m ²)	35.65 ± 11.97	35.44 ± 11.5721	0.94
Education (%)			0.62
High school diploma/GED	23.6	29.6	
Some college	31.6	29.6	
Technical/community	13.1	18.5	
college degree	10.5	14.8	
Bachelor's degree	21.2	7.5	
Master's degree or beyond			
Relationship (%)			0.11
Married	57.8	29.6	
Single	15.8	29.6	
In a relationship	21.1	37.0	
Other	5.3	3.8	
Employment			0.39
Employed FT/PT/on	65.8	66.7	
leave/student	21.0	25.9	
Not currently working	13.2	7.4	
Homemaker/disabled			
Distressed community			0.12
index (%)	5.2	7.4	
Prosperous (below 20)	7.9	18.5	
Comfortable (20.0-40.0)	10.5	0	
Mid-tier (40.1–60.0)	23.7	7.4	
At Risk (60.1–80.0)	52.7	66.7	
Distressed (80.1–100)			
Gestational age at delivery (weeks)	36.86 ± 2.8	37.34 ± 2.95	0.51
Preterm birth (%)			0.43
No	63.1	74	
Yes	36.9	26	
Mode of delivery (%)			0.21
Vaginal	63.2	44.4	
Cesarean section	36.8	55.6	
Labor complications (%)			0.15
No	81.8	63	
Yes	18.2	37	
Birthweight (g)	2992.4 + 747.1	3102.3 ± 585.6	0.53
Infant complications (%)	2772.1 ± / 1/.1	510210 ± 50510	0.71
No	89.2	85.2	0.71
Ves	10.8	14.8	
100	10.0	14.0	

Women with perinatal mood and anxiety disorders have increased IL-17 and $\text{TNF}\alpha$

Biological variables were assessed to determine if they differed in the 2nd or 3rd trimester among women with and without PMADs. At visit 1 there was a significant difference



in IL-17 levels between women with and without PMADs (p = 0.03, Figure 3A). Circulating levels of TNF α were also found to be significantly increased (p = 0.009; Figure 3B), with significant differences at visit 1 (p = 0.04). We also examined, anti-angiogenic growth factors that are commonly associated with a HDP to see if they changed and we did not see any significant differences between groups in circulating soluble endoglin (p = 0.12). There was not a group effect on circulating sFlt-1 levels, but there was a time effect as sFlt-1 significantly increased between visit 1 and visit 2 regardless of maternal mood (p = 0.01, Figure 3C). The same effect occurred with circulating PIGF levels, which increased as pregnancy increased (p < 0.0001, Figure 3D).

Discussion

Maternal mental health is a critical component of a healthy pregnancy. PMADs have a complex pathogenesis with evidence

suggesting that physiological changes triggered by HDP may play a causal role in anxiety and/or depressive symptoms (2). Studies examining women with a HDP have found associations between HDP and PMADs and a correlation with adverse birth outcomes (1, 18). In the current study, our objective was to determine if there is a relationship between PMADs and HDP in a population of women living in Mississippi.

Despite the high prevalence of HDPs in our sample, PMAD was not associated with HDP. These findings are in contrast to findings from previous studies (19). For instance, Dachew et al., examined a large cohort of women and found that women who developed PreE had a 53% increased risk of experiencing antenatal depression relative to women who did not have PreE (20). Similar results were observed when HDP and PMADs were examined in a population-based retrospective study (21). However, when models were adjusted for sociodemographic factors, anxiety was the only mental health disorder associated with hypertension during pregnancy. It is important to note that although an association between HDP and PMAD was not found in the current study, several findings are consistent with the literature. For instance, our data indicated that as maternal age and BMI increased the risk of HDP increased, which has been reported by multiple studies (22, 23). Additionally, black women in our sample were much more likely to develop HDP and to experience a PMAD vs. non-black women (24, 25).

There was not a significant increase rate in the number of cesarean deliveries or infant complications in the HDP patients as noted in previous studies (26); however, women with HDP had babies with significantly lower birth weights which is consistent with the literature (27, 28). Adverse pregnancy outcomes are common among women with HDPs. A systematic review and meta-analysis examining outcomes among pregnant women with chronic hypertension reported a RR of 2.7 (1.9-3.6) for preterm delivery < 37 weeks gestation and an RR of 1.3 (1.1-1.5) for cesarean section (26). Another study investigating perinatal outcomes in women with severe hypertension reported a mean gestational age of 34.5 ± 4.6 weeks at delivery (29), again indicative of pre-term birth. The findings of HDP being associated with preterm birth is supportive of what was found in our patient sample. A large number of studies have investigated the association between PMADs and birth outcomes. Prior studies have found that preterm birth increased in patients with high levels of pregnancy related anxiety (RR) = (2.1, 95% CI: 1.5, 3.0), as was depression during pregnancy (aOR) = 1.71; 95% CI (1.65-1.77) (30, 31).

We examined certain social determinants of health as both social determinants of health and perceived social support are key factors contributing to maternal mental health (2, 32). We did not find an association between employment status and HDP, however, married women were less likely to have a HDP, which is consistent with studies showing that partner/social support is protective against HDP (33).



There were no significant correlations between age and PMAD or DCI and PMAD. To further the contrast between our sample and previous research, there was not an association between PMAD and relationship status, education level or employment status. In contrast, previous studies have shown that being in a relationship, employed, and/or achieving higher levels of education can be protective against anxiety and depression during the perinatal period (34–37).

and As stress can be related to socioeconomic sociodemographic factors we sought to evaluate the associations between perceived stress and selected factors. When we looked at PSS scores and relationship status, married women were more likely to have moderate levels of stress, and women who were single or unmarried while in a relationship were more likely to have severe levels of stress. This finding is consistent with previous studies, which have reported that partner support is protective against stress (36, 37). Our population was different in that there was no significant difference in stress levels between women who were employed vs. those who were unemployed. This contradicts a previous study where unemployed women were found to have higher levels of stress (35). The inconsistency between our population and the literature could be attributed to differences in race, geographical locations, and/or culture.

To determine if there was a difference in inflammatory markers among women with and without PMADs, we evaluated the correlation between immune circulating factors and comorbidity and HDP. Both IL-17 and TNF α , were found to be increased in women with PMADs compared to women without PMAD. This result is consistent with previous studies reporting increased levels of IL-17 in patients with depression (38). In addition, TNF α levels were increased in patients with PMADs; whereas no PMAD relationship was found with sFlt-1 and PIGF. These results suggest that there is a direct relationship between IL-17, TNF α , and PMADs during pregnancy. It has been suggested that IL-17 can cause depression by promoting the production of other pro-inflammatory cytokines such as TNF α which ultimately can interfere with serotonin production (39–41).

Our study had several limitations. For instance, research personnel were prohibited from attending some clinics during the height of the COVID-19 pandemic in 2020. This led to missed blood draws for a small portion of study participants (n = 6). In addition, all women in the current study were free from a history of infant loss, PreE, or a history of anxiety and/or depression (42, 43). This criterion may have contributed to a decreased risk of PMAD, and the current results may represent an underestimate. However, despite the

strict inclusion/exclusion criteria, and the small number of women in the study, the study was adequately powered (> 99%) based on the primary objective to determine a relationship between HDP and PMAD.

To conclude, the current study did not find an association between PMAD and HDP. Patients in distressed zip codes are more stressed, suggesting that socioeconomic factors are tightly linked to mental health. Black women were more likely to have a HDP and develop a PMAD compared to non-black women.

Although the data from our study conflicts with existing literature, one possible explanation for our findings may be within our sample population. Studies have indicated that race, resilience and coping mechanisms all contribute to mental health and cardiovascular outcomes in black individuals (44, 45). It is important to note that the majority of our study sample was composed of non-Hispanic Black women and women who lived in areas considered to be at-risk or distressed. As such, it could be that women in our study are more resilient to variables that are typically considered as stressors. This can lead to a better adaptation to potentially distressing situations and the lack of resources which might have an undesirable effect on mental health and ultimately contribute to adverse pregnancy outcomes. Though there are several factors that can contribute to PMADs or even the self-reporting of PMADs it is important that mental health continue to be evaluated for women during pregnancy and the postpartum period (46). Importantly as studies have indicated that adverse experiences and childhood traumatic events are more frequently recalled during the ante and postpartum period it is important to recognize the utility and administration of selfreport exams/surveys among populations that may be at risk (47). Current studies by our group are building on the study design in the present report with the integration of self-reported adverse childhood experience and brief resilience surveys and including women with a history of PreE or depression/anxiety into the study. However, to truly understand the relationship of HDP, sociodemographic factors and PMAD along with the underlying etiologies and the associated outcomes, a larger more diverse samples must be studied.

Data availability statement

The original contributions presented in this study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by the Institutional Review Board of University of Mississippi Medical Center. The patients/participants provided their written informed consent to participate in this study.

Author contributions

KW and LD contributed to the conception and design of the research. SA, AG, S-KS, SB, and GO conducted the research which was supervised by KW. WK-Y performed the statistical analysis. SA, KW, and LD interpreted the data. SA wrote the first draft of the manuscript. All authors read and contributed to the editing of this manuscript.

Funding

This work was supported in part by the National Institutes of Health (NIH) under Award Numbers P20GM121334 and R01MH116027 to KW and 5T32HL105324-12 to AG.

Acknowledgments

We would like to thank Venessia Johnson, RN and Aleta Washington, RN for their help in recruiting study participants.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Author disclaimer

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/ fpsyt.2022.898003/full#supplementary-material

References

1. Grote N, Bridge J, Gavin A, Melville J, Iyengar S, Katon W. A meta-analysis of depression during pregnancy and the risk of pre-term birth, low birth weight and intrauterine growth restriction. *JAMA Psychiatry*. (2010) 67:1012–24.

2. Araji S, Griffin A, Dixon L, Spencer S, Peavie C, Wallace K. An overview of maternal anxiety during pregnancy and the post-partum period. *J Ment Health Clin Psychol.* (2020) 4:47–56.

3. Kendig S, Keats JP, Hoffman MC, Kay LB, Miller ES, Moore Simas TA, et al. Consensus bundle on maternal mental health: perinatal depression and anxiety. *Obstet Gynecol.* (2017) 129:422–30.

 McKee K, Admon L, Winkelman T, Muzik M, Hall S, Dalton V, et al. Perinatal mood and anxiety disorders, serious metnal illness, and delivery-related health outcomes, United Staes, 2006-2015. BMC Womens Health. (2020) 20:150. doi: 10.1186/s12905-020-00996-6

5. Robertson E, Grace S, Wallington T, Stewart D. Antenatal risk factors for postpartum depression: a synthesis of recent literature. *Gen Hosp Psychiatry.* (2004) 26:289–95. doi: 10.1016/j.genhosppsych.2004.02.006

6. Hu R, Li Y, Zhang Z, Yan W, Coyne J. Antenatal depressive symptomes and the risk of preeclampsia or operative delivieries: a meta-analysis. *PLoS One.* (2015) 10:e0119018. doi: 10.1371/journal.pone.0119018

7. Thombre M, Talge N, Holzman C. Association between pre-pregnancy depression/anxiety symptoms and hypertensive disorders of pregnancy. *J Womens Health*. (2015) 24:228–36.

8. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. (1983) 24:385–96.

9. Cox J, Holden J, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh postnatal depression scale. *Br J Psychiatry.* (1987) 150:782-6.

10. Gibson J, Mckenzie-Mcharg K, Shakespeare J, Price J, Gray R. A systematic review of studies validating the Edinburgh postnatal depression scale in antepartum and postpartum women. *Acta Psychiatr Scand.* (2009) 119:350–64.

11. Somerville S, Dedman K, Hagan R, Oxnam E, Wettinger M, Byrne S, et al. The perinatal anxiety screening scale: development and preliminary validation. *Arch Womens Mental Health*. (2014) 17:443–54.

12. Somerville S, Byrne S, Dedman K, Hagan R, Coo S, Oxnam E, et al. Detecting the severity of perinatal anxiety with the perinatal anxiety screening scale (PASS). *J Affect Disord.* (2015) 186:18–25. doi: 10.1016/j.jad.2015.0 7.012

13. Benzow A, Fikri K, Newman D, O'dell K, Lettieri J. *The Spaces Between Us: The Evolution of American Communities in the New Century.* 4 ed. New York, NY: Economic Innovation Group (2020).

14. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* (2009) 42:377–81. doi: 10.1016/j.jbi.2008.08.010

15. Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. *Neuroscience*. (2013) 246:199–229.

16. D'Souza V, Patil V, Pisal H, Randhir K, Joshi A, Mehendale S, et al. Levels of brain derived neurotrophic factors across gestation in women with preeclampsia. *Int J Dev Neurosci.* (2014) 37:36–40.

17. Christian LM, Mitchell AM, Gillespie SL, Palettas M. Serum brain-derived neurotrophic factor (BDNF) across pregnancy and postpartum: associations with race, depressive symptoms, and low birth weight. *Psychoneuroendocrinology.* (2016) 74:69–76. doi: 10.1016/j.psyneuen.2016.08.025

18. Tsakiridis I, Bousi V, Dagklis T, Sardeli C, Nikolopoulou V, Papazisis G. Epidemiology of antenatal depression among women with high-risk pregnancies due to obstetric complications: a scoping review. *Arch Gynecol Obstet.* (2019) 300:849–59. doi: 10.1007/s00404-019-05270-1

19. Chapuis-de-Andrade S, Moret-Tatay C, De Paula T, Irigaray T, Antonello I, Da Costa B. Psychological factors and coping strategies in pregnancies complicated by hypertension: a cluster-analytic approach. *J Affect Disord.* (2022) 296:89–94. doi: 10.1016/j.jad.2021.09.049

20. Dachew B, Scott J, Alati R. Hypertensive disorders during pregnancy and perinatal mental health symptoms. J Affect Disord Report. (2021) 6:100245.

21. Raina J, El-Messidi A, Badeghiesh A, Tulandi T, Nguyen T, Suarthana E. Pregnancy hypertension and its association with maternal anxiety and mood disorders: a population-based study of 9 million pregnancies. *J Affect Disord*. (2021) 281:533–8. doi: 10.1016/j.jad.2020.10.058

22. Hogan JL, Anglim B, O'dwyer V, Farah N, Stuart B, Turner MJ. Body mass index and hypertensive disorders of pregnancy. *Pregnancy Hypertens*. (2012) 2:28–31.

23. Muto H, Yamamoto R, Ishii K, Kakubari R, Takaoka S, Mabuchi A, et al. Risk assessment of hypertensive disorders in pregnancy with maternal characteristics in early gestation: a single-center cohort study. *Taiwan J Obstet Gynecol.* (2016) 55:341–5. doi: 10.1016/j.tjog.2016.04.009

24. Giurgescu C, Engeland C, Templin T. Symptoms of depression predict negative birth outcomes in african american women: a pilot study. J Midwifery Womens Health. (2015) 60:570–7. doi: 10.1111/jmwh.12337

25. Johnson JD, Louis JM. Does race or ethnicity play a role in the origin, pathophysiology, and outcomes of preeclampsia? An expert review of the literature. *Am J Obstet Gynecol.* (2020) 226:S876–85.

26. Bramham K, Parnell B, Nelson-Piercy C, Seed PT, Poston L, Chappell LC. Chronic hypertension and pregnancy outcomes: systematic review and metaanalysis. *BMJ*. (2014) 348:g2301.

27. Ananth CV, Peedicayil A, Savitz DA. Effect of hypertensive diseases in pregnancy on birthweight, gestational duration, and small-for-gestational-age births. *Epidemiology.* (1995) 6:391–5.

28. Getaneh T, Negesse A, Dessie G, Desta M. The impact of pregnancy induced hypertension on low birth weight in Ethiopia: systematic review and meta-analysis. *Ital J Pediatr.* (2020) 46:174. doi: 10.1186/s13052-020-00926-0

29. Vigil-De Gracia P, Lasso M, Montufar-Rueda C. Perinatal outcome in women with severe chronic hypertension during the second half of pregnancy. *Int J Gynaecol Obstet.* (2004) 85:139–44.

30. Dole N, Savitz D, Hertz-Picciotto I, Siega-Riz A, Mcmahon M, Buekens P. Maternal stress and preterm birth. *Am J Epidemiol.* (2003) 157:14–24.

31. Bansil P, Kuklina EV, Meikle SF, Posner SF, Kourtis AP, Ellington SR, et al. Maternal and fetal outcomes among women with depression. *J Womens Health.* (2010) 19:329–34.

32. Elsenbruch S, Benson S, Rucke M, Rose M, Dudenhausen J, Pincus-Knackstedt M, et al. Social support during pregnancy: effects on maternal depressive symptoms, smoking and pregnancy outcome. *Hum Reprod.* (2007) 22:869–77.

33. Yu Y, Zhang S, Wang G, Hong X, Mallow EB, Walker SO, et al. The combined association of psychosocial stress and chronic hypertension with preeclampsia. *Am J Obstet Gynecol.* (2013) 209:438.e1–12. doi: 10.1016/j.ajog.2013.07.003

34. Ertel KA, Rich-Edwards JW, Koenen KC. Maternal depression in the United States: nationally representative rates and risks. *J Womens Health.* (2011) 20:1609–17.

35. Bloom T, Bullock L, Parsons L. Rural pregnant women's stressors and priorities for stressors and priorities for stress reduction. *Issues Ment Health Nurs*. (2012) 33:813–9. doi: 10.3109/01612840.2012.712087

36. Räisänen S, Lehto SM, Nielsen HS, Gissler M, Kramer MR, Heinonen S. Risk factors for and perinatal outcomes of major depression during pregnancy: a population-based analysis during 2002-2010 in Finland. *BMJ Open.* (2014) 4:e004883.

37. Biaggi A, Conroy S, Pawlby S, Pariante CM. Identifying the women at risk of antenatal anxiety and depression: a systematic review. *J Affect Disord.* (2016) 191:62–77.

38. Chen Y, Jiang T, Chen P, Ouyang J, Xu G, Zeng Z, et al. Emerging tendency towards autoimmune process in major depressive patients: a novel insight from Th17 cells. *Psychiatry Res.* (2011) 188:224–30. doi: 10.1016/j.psychres.2010.10.029

39. Xu S, Cao X. Interleukin-17 and its expanding biological functions. *Cell Mol Immunol.* (2010) 7:164–74.

40. Krishnadas R, Cavanagh J. Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry. (2012) 83:495–502.

41. Roomruangwong C, Anderson G, Berk M, Stoyanov D, Carvalho AF, Maes M. A neuro-immune, neuro-oxidative and neuro-nitrosative model of prenatal and postpartum depression. *Prog Neuropsychopharmacol Biol Psychiatry.* (2018) 81:262–74. doi: 10.1016/j.pnpbp.2017.09.015

42. Hughes P, Turton P, Evans C. Stillbirth as risk factor for depression and anxiety in the subsequent pregnancy: cohort study. *BMJ*. (1999) 318:1721-4.

43. Mostello D, Kallogjeri D, Tungsiripat R, Leet T. Recurrence of preeclampsia: effects of gestational age at delivery of the first pregnancy, body mass index, paternity, and interval between births. *Am J Obstet Gynecol.* (2008) 199:e1–7. doi: 10.1016/j.ajog.2007.11.058

44. Saban K, Motley D, Shawahin L, Mathews H, Tell D, De La Pena P, et al. Preliminary evidence for a race-based stress reduction intervention for Black women at risk for cardiovascular disease. *Complement Ther Med.* (2021) 58:102710. doi: 10.1016/j.ctim.2021.102710

45. Mekawi Y, Carter S, Packard G, Wallace S, Michopoulos V, Powers A. When (passive) acceptance hurts: race-based coping moderates the association between racial discrimination and mental health outcomes among Black Americans. *Psychol Trauma.* (2022) 14:38–46. doi: 10.1037/tra0001077

46. Reuveni I, Lauria M, Monk C, Werner E. The impact of childhood trauma on psychological interventions for depression during pregnancy and postpartum: a systematic review. *Arch Womens Ment Health.* (2021) 24:367–80. doi: 10.1007/s00737-020-01066-4

47. Atzl V, Narayan A, Rivera L, Lieberman A. Adverse childhood experiences and prenatal mental health: types of ACEs and age of maltreatment onset. *J Fam Psychol.* (2019) 33:304–14. doi: 10.1037/fam000 0510